FY2026 Earnings Estimate for Exagen Issued By William Blair

Exagen Inc. (NASDAQ:XGN) – Investment analysts at William Blair issued their FY2026 earnings estimates for shares of Exagen in a research note issued to investors on Wednesday, March 12th. William Blair analyst A. Brackmann anticipates that the company will earn ($0.23) per share for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 target price on shares of Exagen in a report on Monday, January 13th. Canaccord Genuity Group lifted their target price on Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Exagen Stock Down 1.2 %

NASDAQ:XGN opened at $3.33 on Thursday. Exagen has a 1 year low of $1.30 and a 1 year high of $6.22. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock has a market cap of $58.73 million, a price-to-earnings ratio of -3.54 and a beta of 1.40. The stock has a 50-day moving average price of $3.77 and a two-hundred day moving average price of $3.57.

Institutional Investors Weigh In On Exagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank bought a new position in shares of Exagen in the 4th quarter valued at about $3,655,000. Driehaus Capital Management LLC bought a new position in Exagen in the fourth quarter valued at approximately $1,716,000. Stonepine Capital Management LLC increased its position in shares of Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares during the last quarter. Creative Planning bought a new stake in shares of Exagen during the 3rd quarter worth approximately $110,000. Finally, Marshall Wace LLP acquired a new stake in shares of Exagen in the 4th quarter valued at approximately $66,000. 75.25% of the stock is currently owned by institutional investors and hedge funds.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).